Table 1.
Baseline characteristics
| Characteristic | Magnesium (n = 101)* | Placebo (n = 103)† |
|---|---|---|
| Sickle cell anemia type, n (%) | ||
| HgbSS | 92 (91) | 98 (95) |
| HgbSβ0 | 9 (9) | 5 (5) |
| Age, mean (SD) | 13.4 (4.6) | 13.8 (4.8) |
| Age group, n (%) | ||
| 4-11 y | 41 (41) | 40 (39) |
| 12-21 y | 60 (59) | 63 (61) |
| Female, n (%) | 49 (49) | 56 (54) |
| Weight, mean (SD) | 45.4 (19.2) | 46.3 (18.6) |
| Patient history, n (%) | ||
| Treated with hydroxyurea within 3 mo | 63 (62) | 60 (58) |
| History of acute chest syndrome | 74 (73) | 79 (77) |
| History of asthma | 50 (50) | 57 (55) |
| Times hospitalized for a pain crisis in past 3 y, n (%) | ||
| 0 | 8 (8) | 9 (9) |
| 1 | 10 (10) | 17 (17) |
| 2 | 21 (21) | 6 (6) |
| 3 | 14 (14) | 18 (17) |
| 4-5 | 17 (17) | 14 (14) |
| ≥6 | 30 (30) | 38 (37) |
| Days of pain before ED arrival, n (%) | ||
| 0 | 26 (26) | 21 (20) |
| 1 | 36 (36) | 43 (42) |
| 2 | 11 (11) | 14 (14) |
| ≥3 | 28 (28) | 25 (24) |
| Hours from first opioid to study drug, median (IQR) | 7.3 (4.9-11.9) | 7.5 (5.1-12.0) |
| Total opioids (IV morphine equivalents) before first study drug, median (IQR), mg/kg | 0.32 (0.20-0.51) | 0.33 (0.20-0.53) |
| Received ketorolac prior to study drug administration, n (%) | 18 (18) | 23 (22) |
| Hemoglobin, median (IQR), g/100 mL | 8.5 (7.7-9.6) | 8.5 (7.7-9.2) |
| White blood cell count, median (IQR), ×103/μL | 13.5 (9.9-16.4) | 14.0 (11.4-17.7) |
*
One subject in the magnesium group did not have a baseline hemoglobin value; therefore, n = 100 for that result.
†
One subject in the placebo group did not have a hemoglobin or white blood cell value; therefore, n = 102 for that result.